EATG » Hepatitis

Hepatitis

Renal safety of SOF/LDV in combination with TDF in HCV/HIV coinfected patients

Although use of sofosbuvir/ledipasvir (SOF/LDV) may decrease the mean glomerular filtration rate (GFR) in patients who are hepatitis C virus (HCV)/HIV coinfected, concomitant use of tenofovir (TDF) is not associated…

Fibroscan finds one in six patients with hepatitis C in primary care have advanced liver disease

Measuring liver stiffness in primary care using Fibroscan is feasible and detects numerous cases of undiagnosed but advanced liver fibrosis, Australian researchers report in the journal BMJ Open this month.…

HIV and chronic HCV co-infection prevalence in England highest among MSM

Men who have sex with men (MSM) make up the majority of people with chronic hepatitis C virus (HCV) who have co-infection with HIV, according to data from Public Health…

New DAA for hepatitis C effective in large majority of patients with resistance-associated substitutions

People with hepatitis C virus infection whose previous treatment with direct-acting antivirals (DAAs) failed are having success with a fixed-dose combination therapy of sofosbuvir, velpatasvir, and voxilaprevir (Vosevi, Gilead), according…

EMA updates on Viekirax and Victrelis

Viekirax (ombitasvir/paritaprevir/ritonavir) - change to existing contraindication Contraindicated in patients with moderate hepatic impairment Read more here.   ******************* Victrelis (boceprevir) - withdrawal of marketing authorization The marketing authorisation for…

China patent challenge compels Gilead to withdraw key patent claims on sofosbuvir base compound

China patent challenge compels Gilead to withdraw key patent claims on sofosbuvir base compound, opening life-saving hepatitis C treatment access for millions I-MAK’s successful patent challenge against Gilead cracks open…

Cocrystal Pharma commences Phase 2a study evaluating CC-31244 for the treatment of HCV

Cocrystal Pharma commences enrollment and initiates patient dosing in Phase 2a study evaluating CC-31244 for the treatment of HCV - Topline results from Phase 2a study expected to be announced…

Eiger Biopharmaceuticals enrolls first patient in trial for hepatitis D therapy

Eiger BioPharmaceuticals announced the first patient enrollment in its phase 2 study of combination interferon lambda with ritonavir-boosted lonafarnib, according to a press release. “Eiger is developing lonafarnib-based regimens alone…

Enhanced waitlist outcomes in transplant candidates willing to accept HCV+ kidneys

The willingness of hepatitis C RNA-positive (RNA+) waitlisted candidates to accept a kidney from a hepatitis C seropositive donor (HCVD+) was found to have benefits, including an increase in the…

FDA updates hepatitis C drug labeling to include new clinical data

The FDA has approved updates to the labeling for hepatitis C virus (HCV) drug glecaprevir and pibrentasvir (Mavyret) to include new data from 2 clinical studies, according to a press…